- Home
- BIRK vs ACLX Comparison
BIRK vs ACLX Comparison
Compare BIRK & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BIRK | ACLX |
|---|---|---|
| Founded | 1774 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.7B |
| IPO Year | 2023 | 2022 |
Fundamental Metrics
Financial Performance| Metric | BIRK | ACLX |
|---|---|---|
| Price | $43.06 | $115.08 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 15 |
| Target Price | $61.43 | ★ $118.17 |
| AVG Volume (30 Days) | 2.9M | ★ 12.1M |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,286,000.00 |
| Revenue This Year | $13.71 | $342.39 |
| Revenue Next Year | $14.30 | $170.71 |
| P/E Ratio | $17.48 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $31.33 | $60.36 |
| 52 Week High | $57.20 | $115.14 |
Technical Indicators
Market Signals| Indicator | BIRK | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 62.99 | 79.86 |
| Support Level | $40.55 | $63.46 |
| Resistance Level | $46.68 | N/A |
| Average True Range (ATR) | 2.23 | 0.11 |
| MACD | 0.89 | -0.62 |
| Stochastic Oscillator | 86.67 | 84.28 |
Price Performance
Historical ComparisonAbout BIRK Birkenstock Holding plc
Birkenstock is a German footwear brand known for comfort-focused, timeless designs, with 76% of 2022 sales coming from its top five iconic models. Products are made in Europe using sustainable, mostly locally sourced materials. The brand combines orthopedic function with everyday style, appealing to a broad audience. The Americas account for 52% of sales, EMEA 37%, with the remainder coming from Asia-Pacific, which has also the higher future growth expectations.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.